Real-World Lecanemab Safety and Efficacy Data

Duke real-world data: 80% stay on treatment, ARIA 24%, APOE4 homozygotes 4x risk; earlier treatment reduces risk. At-home injectable approved. Access and adherence challenges persist. Recent article reinforces that lecanemab and donanemab are the only two drugs that slow Alzheimer's and work best when caught early. New real-world ARIA incidence data aligns with clinical trial findings.